A comprehensive view of FDA Drug / Device Reviews. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA grants priority review to AbbVie's SBLA for epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody for the treatment of adult relapsed or refractory follicular lymphoma; AbbVie and Genmab are co-developing epcoritamab

FDA accepts Sanofi's supplementary application for priority review of Dupixent as a potential treatment for moderate to severe chronic obstructive pulmonary disease with type 2 inflammation; a decision is expected by June 27, 2024

FDA grants priority review to Regeneron's BLA for linvoseltamab as a treatment for multiple myeloma, decision date is set for August 22, 2024; European medicines agency accepted the drug for review earlier this month

FDA accepts Bristol Myers’ supplemental new drug application for Krazati adagrasib combined with Cetuximab for priority review; the targeted treatment is meant for patients with previously treated KRASG12C-mutated colorectal cancer

Bristol Myers announces acceptance of US and EU regulatory filings for neoadjuvant opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant opdivo in resectable non-small cell lung cancer

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count